BTIG Maintains a Buy on Apogee Therapeutics (APGE)
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best healthcare stocks with the highest upside. BTIG analyst Julian Harrison maintained a Buy rating on Apogee Therapeutics Inc.
Apogee Therapeutics Inc. (APGE)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Driehaus Capital Richard Driehaus | 2,158,502 | $85,757,284 | -7% | 0.61% |
| 2. | Braidwell LP Alex Karnal | 1,438,745 | $57,161,339 | -3% | 1.7% |
| 3. | Perceptive Advisors Joseph Edelman | 1,351,989 | $53,714,523 | +15% | 1.55% |
| 4. | Citadel Investment Group Ken Griffin | 1,169,244 | $46,454,065 | +136% | 0.01% |
| 5. | Leucadia National Ian Cumming And Joseph Steinberg | 568,084 | $22,569,977 | -12% | 0.11% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $49.85 | 12,500 | $623,125.00 | 20,000 | 2024-12-12 | Filing | |
| $49.02 | 7,500 | $367,650.00 | 7,500 | 2024-12-12 | Filing | |
| $17.00 | 1,750,000 | $29,750,000.00 | 1,750,000 | 2023-07-13 | Filing | |
| $17.00 | 892,529 | $15,172,993.00 | 892,529 | 2023-07-13 | Filing | |
| $17.00 | 1,992,734 | $33,876,478.00 | 1,992,734 | 2023-07-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $70.00 | 1,500 | $105,000.00 | 196,371 | 2025-11-25 | Filing | |
| $65.00 | 2,000 | $130,000.00 | 197,871 | 2025-11-14 | Filing | |
| $60.00 | 1,000 | $60,000.00 | 199,871 | 2025-11-11 | Filing | |
| $64.52 | 100 | $6,452.00 | 1,272,987 | 2025-11-13 | Filing | |
| $63.89 | 1,786 | $114,107.54 | 1,273,087 | 2025-11-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,493,321 | $337,439,643 | 18.99% | |
| 2. | 6,916,462 | $274,791,036 | 0.01% | |
| 3. | 4,723,701 | $187,672,640 | 0.03% | |
| 4. | 2,712,097 | $107,751,614 | 1.33% | |
| 5. | 2,686,026 | $106,715,814 | 0% |
News See All
9 Best Healthcare Stocks with the Highest Upside
Talking about how people are feeling the impact of the shutdown, Dr.
RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best strong buy stocks to invest in according to Wall Street. On September 25, RBC Capital initiated coverage of Apogee Therapeutics Inc.
12 Best Strong Buy Stocks to Invest in According to Wall Street
On September 26, Peter Boockvar, chief investment officer at One Point BFG Wealth Partners, appeared on CNBC to talk about the likelihood of the Federal Reserve’s interest rate cuts, new inflation data...
BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best up and coming stocks with huge upside potential.
10 Best Up and Coming Stocks with Huge Upside Potential
On August 20, Andres Garcia-Amaya, Zoe Financial CEO, joined 'The Exchange' on CNBC to discuss how IPO pops will draw in private companies to become public.
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug
Apogee Therapeutics, Inc.
11 Best Future Stocks to Buy Now
Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars.
12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.
Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)
Apogee Therapeutics, Inc. (NASDAQ:APGE) is one of the 11 Hot New Stocks to Invest in Now. On July 7, analyst Edward Nash of Canaccord Genuity reiterated a Buy rating on Apogee Therapeutics, Inc.
Hedge Fund Resource Center Billionaire Hedge Funds
